After rapid advancement of several promising Ebola virus disease vaccine candidates into phase 1 clinical trials, large randomised controlled trials (RCTs) that aim to show that an investigational vaccine prevents the clinical occurrence of Ebola virus disease have been initiated. The recent decline in Ebola virus disease incidence in affected regions is very welcome news from a humanitarian and public health perspective, but it might hamper direct assessment of vaccine effectiveness based on clinical Ebola virus disease endpoints.
No takes yet. Share an insight, caveat, or question.
Krause et al. (2015) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: